Monophosphoryl lipid A (MPL) formulations for the next generation of vaccines

被引：134

作者：

Baldridge, JR ^{[1
]}

Crane, RT ^{[1
]}

机构：

[1] RIBI Immunochem Res Inc, Hamilton, MT 59840 USA

来源：

METHODS | 1999年 / 19卷 / 01期

关键词：

D O I：

10.1006/meth.1999.0834

中图分类号：

Q5 [生物化学];

学科分类号：

071010 ; 081704 ;

摘要：

Many of the latest trends in vaccine development are dependent on immunological adjuvants that mediate and promote a wide variety of immune responses. One promising adjuvant candidate, monophosphoryl lipid A (MPL) immunostimulant, is being investigated with many of these new vaccine approaches in either preclinical or clinical trials. This is possible because different vehicle formulations can significantly influence the type of immunological response MPL promotes. Procedures are provided for formulating MPL in an aqueous vehicle or an oil-in-water emulsion. These two MPL formulations can be beneficial for most vaccine approaches being investigated today. (C) 1999 Academic Press.

引用

页码：103 / 107

页数：5

共 31 条

[1]

AREND WP, 1986, CLIN EXP IMMUNOL, V64, P656

[2]

ASTIZ ME, 1994, J LAB CLIN MED, V123, P89

[3] EFFECT OF MONOPHOSPHORYL LIPID-A ON THE INVITRO FUNCTION OF PERITONEAL LEUKOCYTES FROM UREMIC PATIENTS ON CONTINUOUS AMBULATORY PERITONEAL-DIALYSIS [J].